A comparative clinical evaluation of Erandadi kwath and Amritadi churna in the management of Aamvata with special reference to Rheumatoid Arthritis

Banaras Hindu University1 个研究点分布在 1 个国家目标入组 70 人开始时间: 2025年2月20日最近更新: 2025年1月24日

试验速览

阶段: 2 期
状态: 尚未招募
发起方: Banaras Hindu University
入组人数: 70
试验地点: 1
主要终点: Relief in signs and symptoms of the disease. The

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A total 70 cases of Aamavata will be included in this study which will be randomly divided into 2 groups of 35 patients in each . one group will be prescribed Erandadi kwath ,one will be erandadi kwath with Amritadi churna.

研究设计

研究类型: Interventional
分配方式: Randomized
盲法: None

入排标准

年龄范围: 18.00 Year(s) 至 60.00 Year(s)（—）
性别: All

入选标准

•1.Patients willing to participate in the study.
•2.Patients with age between 18-60 years.
•3.The Patients of RA fulfills the diagnostic and assessment criteria, EULAR criteria
•4.Both Seropositive and seronegative cases of RA.
•5.Patients of both sexes.
•6.Duration of illness at least 1-5 years.7.The patient with clinical feature of Aamvata mentioned in Samhitaâ€™s.
•Angamarda Aruchi Trishna Alasya Gaurava Jwara Apaka Angasoonata.

排除标准

•1.Patients having severe ankylosed joints.
•2.The patients of RA with major complications.
•3.Patients of RA having other infective and non-infective joint disorders.
•4.Patients with H/O less than 1 year and more than 5 years with established disease.
•5.Patients having severe degree of deformity & complications.
•6.Pregnant& lactating mother.
•7.If patients having any allergy to the given drug.
•8.Patients suffering from systemic disorder like (diabetes mellitus, cardiac disease, pulmonary tuberculosis, Essential hypertension, SLE, infectious arthritis.).